TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04802382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: patient's vital signs will be measured on days 1-14 and day 28

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vital Signs
Description: patient's vital signs will be measured on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: patients will provide a blood sample for a hematology blood test on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology blood test
Description: patients will provide a blood sample for a hematology blood test on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hematology blood test
Description: patients will provide a blood sample for a hematology blood test on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemistry blood test
Description: patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Biochemistry blood test
Description: patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEWS score
Description: patient's NEWS score will be evaluated on days 1-14 and day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEWS score
Description: patient's NEWS score will be evaluated on days 1-14 and day 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NEWS score
Description: patient's NEWS score will be evaluated on days 1-14 and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PK test
Description: PK test will be performed on day 1 only (only in Brazil sites)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PK test
Description: PK test will be performed on day 1 only (only in Brazil sites)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: PK test
Description: PK test will be performed on day 1 only (only in Brazil sites)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test for inflammatory markers
Description: patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
Study: NCT05454462

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Investigator's Global Assessment
Description: patient's disease evaluations will be evaluated on all the clinical visits

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Investigator's Global Assessment
Description: patient's disease evaluations will be evaluated on all the clinical visits

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Itch Assessment via PP-NRSj
Description: patient's disease evaluations will be evaluated on all the clinical visits

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Itch Assessment via PP-NRSj
Description: patient's disease evaluations will be evaluated on all the clinical visits

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Itch Assessment via PP-NRSj
Description: patient's disease evaluations will be evaluated on all the clinical visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-diary data
Description: The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
Study: NCT06507605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M
Description: Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
Study: NCT04814524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Wear Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Wear Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04802382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test for inflammatory markers
Description: patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: blood test for inflammatory markers
Description: patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-dimer test
Description: patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
Study: NCT06298591

Intervention type: PROCEDURE
Group type: OTHER
Intervention: co2 laser
Description: laser
Study: NCT04802382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-dimer test
Description: patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: D-dimer test
Description: patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Study: NCT04673422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study: NCT06457880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG BLOCK
Description: Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator Nerve Block
Description: Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
Study: NCT06266078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative PPE
Description: The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional PPE
Description: The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
Study: NCT05648383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Description: Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Description: Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care, including lifestyle recommendations.
Study: NCT05454462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-diary data
Description: The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-diary data
Description: The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
Study: NCT05648383

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care, including lifestyle recommendations.
Study: NCT05214885

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study
Study: NCT04814524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Device
Description: Use VR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Device
Description: Use VR
Study: NCT05830526

Intervention type: OTHER
Group type: OTHER
Intervention: Escape Room
Description: The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room.
Study: NCT05158179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensation testing
Description: Sensation testing tactile aesthesiometer.
Study: NCT05286567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGRN-305
Description: Heat shock protein 90 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (blinded)
Study: NCT06187220

Intervention type: DEVICE
Intervention: Therapeutic Plasma Exchange (PEX)
Description: Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
Study: NCT05313607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed physical therapy
Description: Attention is given to improve motor function, conducted for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed physical therapy
Description: Attention is given to improve motor function, conducted for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: included exercises facilitating hand skills, conducted for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: included exercises facilitating hand skills, conducted for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: aimed to improve the affected upper extremity function, conducted for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: basically focuses on upper extremity strength training conducted for 30 minutes
Study: NCT04802382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAS scale
Description: patient's VAS scale will be evaluated on days 1-14, day 21, and day 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VAS scale
Description: patient's VAS scale will be evaluated on days 1-14, day 21, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine pregnancy test for women of childbearing potential
Description: patients will provide a urine sample for a urine pregnancy test on days 1, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine pregnancy test for women of childbearing potential
Description: patients will provide a urine sample for a urine pregnancy test on days 1, and day 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urine pregnancy test for women of childbearing potential
Description: patients will provide a urine sample for a urine pregnancy test on days 1, and day 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: patients will undergo an ECG examination on days 1, and day 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: patients will undergo an ECG examination on days 1, and day 28

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: patients will undergo an ECG examination on days 1, and day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19-Impact on Quality of Life Questionnaire
Description: patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19-Impact on Quality of Life Questionnaire
Description: patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Impact on Quality of Life Questionnaire
Description: patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CimetrA-1
Description: patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CimetrA-2
Description: patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Study: NCT05216770

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Laryngeal sensory block with topical bupivacaine
Description: Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal sensory block with topical bupivacaine
Description: Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
Study: NCT05710731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of simulation in urinary catheterization training
Description: To train students on urinary catheterization by using one of 3 different simulation methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of simulation in urinary catheterization training
Description: To train students on urinary catheterization by using one of 3 different simulation methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of simulation in urinary catheterization training
Description: To train students on urinary catheterization by using one of 3 different simulation methods.
Study: NCT06519240

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)
Description: Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)
Description: Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
Study: NCT05145751

Intervention type: OTHER
Intervention: Simple inflammatory biomarkers measurement
Description: In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
Study: NCT05746091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wrist arthroscopy
Description: Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
Study: NCT04742530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted Evening Exercise
Description: A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fed Evening Exercise
Description: A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fed Morning Exercise
Description: A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
Study: NCT06351423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forest Bathing (FB)
Description: The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session.
Study: NCT05165459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous leg ulcer treatment with adipous SVF
Description: The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.